Anesthesia, LocalPhase 4ROPIWA-2NCT07342010
Bicarbonate Addition to Lidocaine-Epinephrine in Surgery Under WALANT
A Phase 4 study testing Ambulatory surgery under Lidocaine with epinephrine alone and Ambulatory surgery under lidocaine with epinephrine plus bicarbonate in people with Anesthesia, Local and Hand Surgery, run by Centre Hospitalier Universitaire de Nīmes at 1 site in France.
Trial summary
Distal upper limb and distal lower limb surgery performed under local anesthesia using the WALANT technique (Wide Awake Local Anesthesia No Tourniquet) has become standard practice in ambulatory orthopedic surgery. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Anesthesia, Local, Hand Surgery, Foot Surgery
- What is being tested?
- Ambulatory surgery under Lidocaine with epinephrine alone and Ambulatory surgery under lidocaine with epinephrine plus bicarbonate
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 150 participants
- Where
- 1 siteFrance
- Study dates
- 1 Feb 2026to 1 Feb 2027
- Phase
- Phase 4
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults (≥18 years) eligible for ambulatory surgery under WALANT for Hand surgery (including carpal tunnel release, trigger finger release, or Dupuytren's disease surgery) and foot surgery (including hallux valgus or hallux rigidus.)
- Provision of free and informed consent.
- Signed informed consent form.
- Affiliation with or beneficiary of a health insurance system
Who cannot join
- Ischemic vascular disorders, including severe Raynaud's disease, Buerger's disease, or diabetic microangiopathy.
- Scleroderma.
- Known allergy to lidocaine or potential cross-reactivity with other amide-type local anesthetics.
- Severe hepatic impairment.
- Acute porphyria.
- Intravascular administration of local anesthesia.
Show all 19Show fewer
- Local anesthetic infiltration at the level of the extremities.
- Coronary artery disease.
- Ventricular arrhythmias.
- Severe arterial hypertension.
- Obstructive cardiomyopathy.
- Hyperthyroidism.
- Hypovolemia.
- Participation in an interventional clinical research study classified as category 1 (RIPH category 1).
- Ongoing exclusion period related to participation in another clinical study.
- Legal protection status (guardianship, trusteeship, or judicial protection).
- Inability to provide informed consent.
- Inability to receive or understand adequate study information.
- Pregnancy, labor, or breastfeeding. Women of childbearing potential will undergo a urine pregnancy test prior to inclusion.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site
Yann GRICOURT
Nîmes, Gard, 30029
Yann GRICOURT, Dr., +33466683050, gricourt.yann@gmail.com
Anissa MEGZARI, +33466683050, drc@chu-nimes.fr
About this study
Official title: Evaluation of the Effect of Lidocaine With Adrenaline, With or Without Bicarbonate, on Early Postoperative Recovery in WALLANT-type Outpatient Hand and Foot Surgery: A Prospective, Randomised, Double-blind, Single-centre Non-inferiority Study.
Distal upper limb and distal lower limb surgery performed under local anesthesia using the WALANT technique (Wide Awake Local Anesthesia No Tourniquet) has become standard practice in ambulatory orthopedic surgery. Current infiltration mixtures used by orthopedic surgeons include lidocaine-epinephrine with the addition of 8.4% bicarbonate to reduce injection-related pain and improve analgesia duration. However, the clinical benefit of bicarbonate addition remains insufficiently supported by evidence and may increase preparation complexity and risk, including potential solution crystallization.
The aim of the ROPIWA-2 trial is to investigate whether omission of bicarbonate from the local infiltration mixture is noninferior to bicarbonate addition with respect to early postoperative quality of recovery on postoperative day 1. We hypothesize that removing bicarbonate does not impair postoperative quality of recovery after ambulatory hand and foot surgery under WALANT. Expected benefits include confirmation of a simpler, ready-to-use anesthetic solution that is easier and safer to use, without reducing patient comfort or recovery. The expected risks are those normally associated with this type of procedure.
Read the detailed description
Study context WALANT (Wide Awake Local Anesthesia No Tourniquet) is increasingly used for ambulatory hand and foot surgery, as it allows surgery without preoperative fasting and provides effective local anesthesia without a tourniquet, while promoting early functional recovery.
Sodium bicarbonate is commonly added to lidocaine-epinephrine solutions to reduce injection-related pain and prolong the duration of the anesthetic block. However, its clinical benefit remains uncertain and may increase preparation complexity.
Therefore, a robust methodological assessment of the impact of bicarbonate omission on early postoperative recovery is warranted in ambulatory WALANT surgery.
Primary objective To evaluate the effect of two WALANT local anesthesia protocols (lidocaine-epinephrine with or without bicarbonate addition) on early postoperative recovery at 24 hours after ambulatory hand and foot surgery.
Key secondary objectives A) Sensory block onset time. B) Intraoperative anesthetic block failure rate. C) Pain related to injection of the WALANT anesthetic solution. D) Intraoperative pain intensity. E) Patient satisfaction with perioperative care. F) Postoperative pain scores. G) Postoperative analgesic consumption, including opioids. H) Duration of the anesthetic block I) Postoperative adverse events.
Study design and conduct This prospective, single-center, randomized, double-blind, noninferiority trial will compare two 20 mL WALANT (Wide Awake Local Anesthesia No Tourniquet) solutions in patients scheduled for distal hand or foot ambulatory surgery.
The intervention group will receive lidocaine 5 mg/mL combined with epinephrine 0.005 mg/mL (18 mL of solution mixed with 2 mL of saline as placebo), whereas the control group will receive a similar solution including 8.4% bicarbonate (18 mL of solution mixed with 2 mL of bicarbonate). Both solutions will be administered by orthopedic surgeons prior to surgical incision.
Additional solution will be administered if sensory block is insufficient prior to incision.The maximum total lidocaine dose per patient will not exceed 800 mg in adults, in accordance with the approved labeling and standard clinical use of the drug.
Adults (≥18 years) eligible for ambulatory WALANT procedures (hand or selected foot surgeries) will be screened during the preoperative orthopedic consultation (pre-inclusion visit). All eligible patients will receive oral and written information, with at least one day between the pre-inclusion and inclusion visits to allow time for reflection and informed consent.
After written consent is obtained, patients will be randomized in a 1:1 ratio to the control group (with bicarbonate) or the intervention group (without bicarbonate). The surgical procedure under WALANT will be performed by orthopedic surgeon investigators.
Preoperative pain intensity (NRS), surgery-related anxiety (NRS), and the QuickDASH score will be recorded prior to the surgical procedure. Before hospital discharge, postoperative pain and patient satisfaction will be assessed. All patients will receive a standardized postoperative analgesic regimen.
Postoperative follow-up calls conducted by the clinical research associate will occur at 24 hours (NRS pain score, QoR-15 score, duration of the analgesic block, analgesic consumption, and adverse events) and at 48 hours (NRS pain score and adverse events). Study participation will end after the 48-hour follow-up call.
The estimated sample size is 150 patients, with 75 patients in each study arm. For the primary outcome, the noninferiority margin for the QoR-15 score is set at 6 points.
- Conditions
- Anesthesia, Local, Hand Surgery, Foot Surgery, Walant Surgery
- Being tested
- Ambulatory surgery under Lidocaine with epinephrine alone, Ambulatory surgery under lidocaine with epinephrine plus bicarbonate
- Keywords
- lidocaine,, bicarbonates,, Quality of recovery, Walant
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ambulatory surgery under Lidocaine with epinephrine aloneCombination product
Also called Local infiltration with lidocaine-epinephrine
The anesthetic solution will consist of lidocaine 5 mg/mL combined with epinephrine 0.005 mg/mL, administered as 18 mL (90 mg of lidocaine) plus 2 mL of saline (placebo), for a total volume of 20 mL Additional solution will be administered if sensory block is insufficient prior to incision.
Ambulatory surgery under lidocaine with epinephrine plus bicarbonateCombination product
Also called Local infiltration with lidocaine-epinephrine and bicarbonate
The anesthetic solution will consist of lidocaine 5 mg/mL combined with epinephrine 0.005 mg/mL, administered as 18 mL (90 mg of lidocaine) plus 2 mL of 8.4% bicarbonate, for a total volume of 20 mL.
Additional solution will be administered if sensory block is insufficient prior to incision.
| Study group | Role | What they receive |
|---|---|---|
| Patients undergoing hand and foot surgery with lidocaine and Epinephrine alone | Experimental | Patients undergoing hand and foot surgery under WALANT using lidocaine 5 mg/mL combined with epinephrine 0.005 mg/mL, without bicarbonate. Receives: Combination Product: Ambulatory surgery under Lidocaine with epinephrine alone |
| Patients undergoing hand and foot surgery with buffered lidocaine | Active comparator | Patients undergoing hand and foot surgery under WALANT using lidocaine 5 mg/mL combined with epinephrine 0.005 mg/mL, with bicarbonate. Receives: Combination Product: Ambulatory surgery under lidocaine with epinephrine plus bicarbonate |
What is being measured
The primary outcome is the main question the study is designed to answer.
QoR-15 score, assessed at 24 hours postoperatively in both study arms
QoR-15 score, assessed at 24 hours postoperatively in both study arms. This validated questionnaire includes 15 items covering five dimensions: pain, physical comfort, physical independence, psychological support, and emotional state. Each item is rated on a 1-10 scale, with a total score ranging from 15 to 150.
Measured: 24 hours after surgery
Secondary outcomes (9)
Sensory block onset time
Anesthetic block onset time: time (in minutes) from the initial injection to complete sensory block of the surgical area, defined as absence of sensation to pinprick testing performed at 5-minute intervals by the surgeon.
Measured: Day 0
Intraoperative anesthetic block failure rate
Defined as the need for rescue intraoperative reinjection of local anesthetic solution by the surgeon due to persistent sensation during anesthetic block testing using nociceptive stimuli (yes/no).
Measured: Day0
Pain related to injection of the WALANT anesthetic solution.
Patient self-assessment of pain experienced during WALANT administration, measured using a Numeric Rating Scale (NRS) from 0 (no pain) to 10 (worst imaginable pain).
Measured: Day 0
Intraoperative pain intensity
Patient self-assessment of pain experienced during the surgical procedure, measured using a Numeric Rating Scale (NRS) from 0 (no pain) to 10 (worst imaginable pain).
Measured: Day 0
Patient satisfaction with perioperative care
Patient self-assessment of satisfaction with perioperative management, measured using a Numeric Rating Scale (NRS) from 0 (not satisfied at all) to 10 (completely satisfied).
Measured: Day 0
Postoperative pain scores
Patient self-assessment of pain intensity measured using a Numeric Rating Scale (NRS) from 0 (no pain) to 10 (worst imaginable pain) at postoperative day 0 (hospital discharge), postoperative day 1, and postoperative day 2.
Measured: Day 2
Postoperative analgesic consumption, including opioids
Total consumption (in milligrams) of paracetamol and ketoprofen during the first 48 postoperative hours, as well as tramadol consumption (in milligrams) during the same period.
Measured: Day 2
Duration of the anesthetic block
Time (in minutes) from the initial anesthetic solution injection to block resolution, defined by the patient-reported onset of postoperative pain (patient self-assessment).
Measured: Day 1
Postoperative adverse events
Occurrence (yes/no) of the following postoperative complications from surgery to postoperative day 2:: hematoma, bleeding, wound dehiscence, paresthesias, nausea, vomiting, rehospitalization, surgical site infection, or other postoperative complications.
Measured: Day 2
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jan 2026
- Study start1 Feb 2026 (estimated)
- Primary completion1 Feb 2027 (estimated)
- Study completion1 Feb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Anesthesia, LocalStudies of the same condition, open and under way.
- More trials run by Centre Hospitalier Universitaire de NīmesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Prospective, single-center, randomized (1:1 ratio), double-blind, noninferiority trial comparing two WALANT solutions (with or without bicarbonate addition) in patients scheduled for distal hand or foot ambulatory surgery.
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire de Nīmes
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07342010
- Sponsor's protocol ID
- 2024-519650-36-00
- Acronym
- ROPIWA-2
- Status last verified
- Jan 2026
- First submitted
- 6 Jan 2026
- Last updated
- 15 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 15 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Effect of Lidocaine With Adrenaline, With or Without Bicarbonate, on Early Postoperative Recovery in WALLANT-type Outpatient Hand and Foot Surgery: A Prospective, Randomised, Double-blind, Single-centre Non-inferiority Study.
- ClinicalTrials.gov ID
- NCT07342010
- Acronym / sponsor ID
- ROPIWA-2 / 2024-519650-36-00
- Conditions
- Anesthesia, Local, Hand Surgery, Foot Surgery, Walant Surgery
- Keywords
- lidocaine,, bicarbonates,, Quality of recovery, Walant
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- Centre Hospitalier Universitaire de NīmesUniversity, hospital or other
- Study start
- 1 Feb 2026 (estimated)
- Primary completion
- 1 Feb 2027 (estimated)
- Study completion
- 1 Feb 2027 (estimated)
- First posted
- 15 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Distal upper limb and distal lower limb surgery performed under local anesthesia using the WALANT technique (Wide Awake Local Anesthesia No Tourniquet) has become standard practice in ambulatory orthopedic surgery. Current infiltration mixtures used by orthopedic surgeons include lidocaine-epinephrine with the addition of 8.4% bicarbonate to reduce injection-related pain and improve analgesia duration. However, the clinical benefit of bicarbonate addition remains insufficiently supported by evidence and may increase preparation complexity and risk, including potential solution crystallization.
The aim of the ROPIWA-2 trial is to investigate whether omission of bicarbonate from the local infiltration mixture is noninferior to bicarbonate addition with respect to early postoperative quality of recovery on postoperative day 1. We hypothesize that removing bicarbonate does not impair postoperative quality of recovery after ambulatory hand and foot surgery under WALANT. Expected benefits include confirmation of a simpler, ready-to-use anesthetic solution that is easier and safer to use, without reducing patient comfort or recovery. The expected risks are those normally associated with this type of procedure.
Detailed description
Study context WALANT (Wide Awake Local Anesthesia No Tourniquet) is increasingly used for ambulatory hand and foot surgery, as it allows surgery without preoperative fasting and provides effective local anesthesia without a tourniquet, while promoting early functional recovery.
Sodium bicarbonate is commonly added to lidocaine-epinephrine solutions to reduce injection-related pain and prolong the duration of the anesthetic block. However, its clinical benefit remains uncertain and may increase preparation complexity.
Therefore, a robust methodological assessment of the impact of bicarbonate omission on early postoperative recovery is warranted in ambulatory WALANT surgery.
Primary objective To evaluate the effect of two WALANT local anesthesia protocols (lidocaine-epinephrine with or without bicarbonate addition) on early postoperative recovery at 24 hours after ambulatory hand and foot surgery.
Key secondary objectives A) Sensory block onset time. B) Intraoperative anesthetic block failure rate. C) Pain related to injection of the WALANT anesthetic solution. D) Intraoperative pain intensity. E) Patient satisfaction with perioperative care. F) Postoperative pain scores. G) Postoperative analgesic consumption, including opioids. H) Duration of the anesthetic block I) Postoperative adverse events.
Study design and conduct This prospective, single-center, randomized, double-blind, noninferiority trial will compare two 20 mL WALANT (Wide Awake Local Anesthesia No Tourniquet) solutions in patients scheduled for distal hand or foot ambulatory surgery.
The intervention group will receive lidocaine 5 mg/mL combined with epinephrine 0.005 mg/mL (18 mL of solution mixed with 2 mL of saline as placebo), whereas the control group will receive a similar solution including 8.4% bicarbonate (18 mL of solution mixed with 2 mL of bicarbonate). Both solutions will be administered by orthopedic surgeons prior to surgical incision.
Additional solution will be administered if sensory block is insufficient prior to incision.The maximum total lidocaine dose per patient will not exceed 800 mg in adults, in accordance with the approved labeling and standard clinical use of the drug.
Adults (≥18 years) eligible for ambulatory WALANT procedures (hand or selected foot surgeries) will be screened during the preoperative orthopedic consultation (pre-inclusion visit). All eligible patients will receive oral and written information, with at least one day between the pre-inclusion and inclusion visits to allow time for reflection and informed consent.
After written consent is obtained, patients will be randomized in a 1:1 ratio to the control group (with bicarbonate) or the intervention group (without bicarbonate). The surgical procedure under WALANT will be performed by orthopedic surgeon investigators.
Preoperative pain intensity (NRS), surgery-related anxiety (NRS), and the QuickDASH score will be recorded prior to the surgical procedure. Before hospital discharge, postoperative pain and patient satisfaction will be assessed. All patients will receive a standardized postoperative analgesic regimen.
Postoperative follow-up calls conducted by the clinical research associate will occur at 24 hours (NRS pain score, QoR-15 score, duration of the analgesic block, analgesic consumption, and adverse events) and at 48 hours (NRS pain score and adverse events). Study participation will end after the 48-hour follow-up call.
The estimated sample size is 150 patients, with 75 patients in each study arm. For the primary outcome, the noninferiority margin for the QoR-15 score is set at 6 points.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Prospective, single-center, randomized (1:1 ratio), double-blind, noninferiority trial comparing two WALANT solutions (with or without bicarbonate addition) in patients scheduled for distal hand or foot ambulatory surgery.
| Arm | Type | Receives |
|---|---|---|
| Patients undergoing hand and foot surgery with lidocaine and Epinephrine alone | Experimental | Combination Product: Ambulatory surgery under Lidocaine with epinephrine alonePatients undergoing hand and foot surgery under WALANT using lidocaine 5 mg/mL combined with epinephrine 0.005 mg/mL, without bicarbonate. |
| Patients undergoing hand and foot surgery with buffered lidocaine | Active comparator | Combination Product: Ambulatory surgery under lidocaine with epinephrine plus bicarbonatePatients undergoing hand and foot surgery under WALANT using lidocaine 5 mg/mL combined with epinephrine 0.005 mg/mL, with bicarbonate. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Adults (≥18 years) eligible for ambulatory surgery under WALANT for Hand surgery (including carpal tunnel release, trigger finger release, or Dupuytren's disease surgery) and foot surgery (including hallux valgus or hallux rigidus.)
- Provision of free and informed consent.
- Signed informed consent form.
- Affiliation with or beneficiary of a health insurance system
Key exclusion criteria (19 listed)
- Ischemic vascular disorders, including severe Raynaud's disease, Buerger's disease, or diabetic microangiopathy.
- Scleroderma.
- Known allergy to lidocaine or potential cross-reactivity with other amide-type local anesthetics.
- Severe hepatic impairment.
- Acute porphyria.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ambulatory surgery under Lidocaine with epinephrine aloneAlso: Local infiltration with lidocaine-epinephrineThe anesthetic solution will consist of lidocaine 5 mg/mL combined with epinephrine 0.005 mg/mL, administered as 18 mL (90 mg of lidocaine) plus 2 mL of saline (placebo), for a total volume of 20 mL Additional solution will be administered if sensory block is insufficient prior to incision. | Combination product | Patients undergoing hand and foot surgery with lidocaine and Epinephrine alone |
| Ambulatory surgery under lidocaine with epinephrine plus bicarbonateAlso: Local infiltration with lidocaine-epinephrine and bicarbonateThe anesthetic solution will consist of lidocaine 5 mg/mL combined with epinephrine 0.005 mg/mL, administered as 18 mL (90 mg of lidocaine) plus 2 mL of 8.4% bicarbonate, for a total volume of 20 mL. Additional solution will be administered if sensory block is insufficient prior to incision. | Combination product | Patients undergoing hand and foot surgery with buffered lidocaine |
Primary outcome
QoR-15 score, assessed at 24 hours postoperatively in both study arms
Time frame: 24 hours after surgery
QoR-15 score, assessed at 24 hours postoperatively in both study arms. This validated questionnaire includes 15 items covering five dimensions: pain, physical comfort, physical independence, psychological support, and emotional state. Each item is rated on a 1-10 scale, with a total score ranging from 15 to 150.
9 secondary outcomes
Sensory block onset time
Time frame: Day 0
Intraoperative anesthetic block failure rate
Time frame: Day0
Pain related to injection of the WALANT anesthetic solution.
Time frame: Day 0
Intraoperative pain intensity
Time frame: Day 0
Patient satisfaction with perioperative care
Time frame: Day 0
Postoperative pain scores
Time frame: Day 2
Postoperative analgesic consumption, including opioids
Time frame: Day 2
Duration of the anesthetic block
Time frame: Day 1
Postoperative adverse events
Time frame: Day 2
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jan 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Anesthesia, Local
RecruitingPhase 4
Lidocaine Infiltration and Neuroimmunomodulation in Head and Neck Cancer Surgery
Head and Neck Cancer (H&N)
Recruiting
Minimum Effective Local Anesthetic Volume for Ultrasound Guided Superior Trunk Block
Musculoskeletal Diseases or Conditions
RecruitingPhase 3
A Study of Changes to Prostate Procedures
Prostate Cancer
Not yet recruiting
Magnesium Sulphate as an Adjuvant in Combined Costoclavicular Block and Suprascapular Block Versus Interscalene Block for Ambulatory Shoulder Arthroscopy
Postoperative Pain, Shoulder Arthroscopy
Recruiting
Comparison of Spinal Anesthesia With Intrathecal Morphine Versus PENG Block With or Without Dexamethasone in Hip Arthroplasty
Arthropathy of Hip, Hip Osteoarthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Ambulatory surgery under Lidocaine with epinephrine alone and Ambulatory surgery under lidocaine with epinephrine plus bicarbonate in people with Anesthesia, Local and Hand Surgery, run by Centre Hospitalier Universitaire de Nīmes at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 15 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Yann GRICOURT, Dr. (+334.66.68.30.50, gricourt.yann@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
QoR-15 score, assessed at 24 hours postoperatively in both study arms (time frame: 24 hours after surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jan 2026.